Key result
Gene expression profiling identified 41, 103, and 94 differentially expressed probes in chylomicronemia patients with 0, 1 to 3, and ≥4 prior acute pancreatitis episodes, respectively, compared to healthy controls.
Why the study?
The number of pancreatitis episodes varies significantly between patients with chylomicronemia, prompting an investigation into gene expression profiles of recurrent acute pancreatitis in these patients.
Does gene expression profiling identify biomarkers associated with recurrent acute pancreatitis in patients with sustained chylomicronemia?
Observational (n=62)
No
Does gene expression profiling identify biomarkers associated with recurrent acute pancreatitis in patients with sustained chylomicronemia?
p-value: p=<0.01
Gene expression profiling identified specific biomarkers involved in inflammatory and lipoprotein kinetic pathways that are associated with recurrent acute pancreatitis in patients with sustained chylomicronemia.
Supports candidate biomarkers for recurrent pancreatitis in chylomicronemia; hypothesis-generating and requires prospective validation before clinical use.
A fasting triglyceridemia >10 mmol/L is associated with chylomicronemia (CM) and an increased recurrent acute pancreatitis (RAP) risk. The number of pancreatitis episodes varies significantly between patients with CM. The objective of this study was to investigate gene expression profiles of RAP in patients with CM. A total of 47 CM subjects participated in this study. Prior to the analyses, all patients were divided into three groups covering a wide spectrum of RAP: 0 (n = 21), 1-3 (n = 10) or >4 (n = 16) pancreatitis episodes. Gene expression profiles were compared to those of 15 healthy normolipidemic controls. Differential expression moderated T-tests between studied groups were performed using a linear model of the Bioconductor package Limma. The False discovery rate was controlled using the Benjamini-Hochberg procedure. At a p-value <0.01, a false discovery rate of 5% and a >2-fold change expression significance levels, a set of 41 probes have been found differentially expressed in CM subjects with no pancreatitis, 103 in the CM group with 1 to 3 pancreatitis, and 94 in the group with ≥4 pancreatitis compared to healthy controls. Of the identified annotated probes, 14 are shared by all CM groups; 3 are specific to CM with no pancreatitis; 11 are specific to CM with 1 to 3 pancreatitis, and 17 are specific to CM with ≥4 pancreatitis. Most of the annotated biomarkers are involved in inflammatory, immune, lipoprotein kinetics or signalling biological pathways. These results reveal gene expression signatures of RAP in patients with CM.
No takes yet. Share an insight, caveat, or question.
Tremblay et al. (2020) conducted an observational in Sustained chylomicronemia and recurrent acute pancreatitis (n=62). Recurrent acute pancreatitis episodes vs. Healthy normolipidemic controls and chylomicronemia patients without pancreatitis was evaluated on Differentially expressed gene probes (p=<0.01). Gene expression profiling identified 41, 103, and 94 differentially expressed probes in chylomicronemia patients with 0, 1 to 3, and ≥4 prior acute pancreatitis episodes, respectively, compared to healthy controls.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: